
MEDIA RELEASE

Ypsomed Holding AG successfully completes its capital increase

Burgdorf, July 3, 2009, 05:45 p.m. – Ypsomed Holding AG has successfully completed a capital increase of CHF 96.3 million as approved by the General Meeting of Shareholders on June 24, 2009. As a result of the transaction Ypsomed's consolidated equity ratio will increase to 82.9%. All of the 1'405'526 new registered shares have been subscribed for as part of the rights offering by existing shareholders and by the majority shareholder respectively. After the expiration of the subscription period on July 3, 2009 (12:00 CET), the subscription price was set at CHF 68.50 per registered share. This corresponds to a discount of 2.1% compared to the last price paid at the end of the subscription period.

Exercise of subscription right

Based on their subscription rights the current shareholders have subscribed for 1'155'313 new registered shares. For an "at market" capital increase, this corresponds to a high exercise ratio of 82.2%. The remaining 250'213 registered shares have been acquired by the majority shareholder at the subscription price. After the completion of the capital increase including an increase of the par value, Ypsomed Holding AG will have 12'649'739 registered shares with a par value of CHF 15, of which Dr. h.c. Willy Michel and Techpharma Management AG together hold a total of 73.0%.

Use of the funds

Through the conversion of part of the shareholder loan provided by the majority shareholder, this loan will be reduced by CHF 85.5 million to CHF 54.5 million. Taking into account the net proceeds of CHF 9.1 million, the equity ratio will increase to a very high 82.9%. Ypsomed Holding AG intends to use the funds from the capital increase for continued internal and external growth, in particular for up-front investments in setting up the production for new injection systems as well as for the imminent market development for the new Pura™ blood glucose monitoring system from Bionime in Europe. The possibility of increasing the stake in Bionime is also being examined.

Trading starts July 9, 2009

It is expected that the new registered shares will be listed and traded on the SIX Swiss Exchange AG and BX Berne eXchange starting on July 9, 2009.

Further information is available from Daniel Kusio, Head of Investor & Public Relations at Ypsomed Holding AG, tel. +41 34 424 4143 or tel. +41 34 424 4111. This media release as well as additional information are available in electronic format at www.ypsomed.com.

Important Notice

"This media release constitutes neither an offer to sell nor a solicitation to buy any securities, and it does not constitute a prospectus within the meaning of Article 652a of the Swiss Code of Obligations or within the meaning of the Listing Rules of the SIX Swiss Exchange. Investors should make their investment decision to buy or subscribe to shares solely on the basis of a prospectus, and the offer of securities of Ypsomed Holding AG will be made solely by means of a prospectus to be published by the company and that will be made available free of charge.

This media release is not being issued in the United States of America and must not be distributed to U.S. persons or publications with a general circulation in the United States. This media release does not constitute an offer or invitation to purchase any securities in the United States. The securities of Ypsomed Holding AG have not been registered under United States securities laws and may not be offered, sold or delivered within the United States or to U.S. persons absent from registration under or an applicable exemption from the registration requirements of United States securities laws. Investors are furthermore advised to consult their bank or financial advisor.

This media release contains specific forward-looking statements, e.g., statements including terms like "believe", "assume", "expect" or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments."